Abstract. Phenethyl isothiocyanate (PEITC)-a naturally occurring isothiocyanate in cruciferous vegetables-has been extensively studied as a chemopreventive agent in several preclinical species and in humans. Pharmacokinetic features of unchanged PEITC are (I) linear and first-order absorption, (II) high protein binding and capacity-limited tissue distribution, and (III) reversible metabolism and capacity-limited hepatic elimination. Membrane transport of PEITC is mediated by BCRP, multidrug resistance-associated protein (MRP) 1, and MRP2 transporters belonging to the ATP-binding-cassette (ABC) family. PEITC is metabolized by glutathione S-transferase (GST) in the liver, with the glutathione conjugate of PEITC undergoing further conversion to mercapturic acid by N-acetyl transferase in rats and humans. PEITC modulates the activity and expression of numerous phase I and phase II drugmetabolizing enzymes and can inhibit the metabolism of procarcinogens to form carcinogens and increase carcinogen elimination. In recent years, several in vitro and in vivo studies have elucidated molecular mechanisms underlying the pharmacodynamics of PEITC in breast cancer that include cancer cell apoptosis by upregulation of apoptotic genes, cell cycle arrest at G2/M phase by generation of reactive oxygen species and depletion of intracellular glutathione, downregulation of the estrogen receptor, decrease in sensitivity to estrogen, and inhibition of tumor metastasis. Inhibition of angiogenesis is one of the recently reported mechanisms of breast cancer prevention by PEITC. Complex pharmacokinetics and pharmacodynamics of PEITC necessitate a systems-biology approach in parallel with PK/PD modeling to develop PEITC as a therapeutic agent for treating cancers.
INTRODUCTION
Isothiocyanates (ITCs) are formed by the breakdown of glucosinolates, which are major constituents of cruciferous vegetables (watercress, cabbage, brussels sprouts, cauliflower, etc.) (1) . The enzyme myrosinase in plants and the microflora in the gastrointestinal tract are responsible for the release of ITCs from glucosinolates after physical damage to cruciferous vegetables (harvesting, cutting, or chewing) and after dietary ingestion, respectively (1, 2) . ITCs have drawn the attention of the scientific community since the mid-1980s due to their anticancer potential (2) (3) (4) (5) . ITCs inhibit carcinogenesis by several mechanisms including (I) inhibition of carcinogen metabolism by drug-metabolizing enzymes (DMEs) (6) , (II) apoptosis of cancer cells (7) , and (III) cell cycle inhibition (8) . Recent evidence also suggests that ITCs are anti-angiogenic, and this may contribute to their cancer preventive effects (9).
The two major ITCs present in cruciferous vegetables that have been extensively studied are sulforaphane and phenethyl isothiocyanate. This review will focus on phenethyl isothiocyanate (PEITC) (Fig. 1) , which is derived from the hydrolysis of its glucosinolate precursor gluconasturtiin (2) . In humans, consumption of dietary glucosinolates is estimated to be about 300 mg/day (2) from various cruciferous vegetables and, for every 56.8 g of watercress consumed, approximately 12 mg of PEITC is released (10) . PEITC is a low molecular weight (MW=163.2 g/mol) compound and is fairly lipophilic (logP=3. 47) . Of all the ITCs, PEITC is one of the most comprehensively studied ITCs in various cancers (5, 7, (11) (12) (13) (14) and is currently being evaluated in a National Cancer Institute phase II clinical trial to prevent lung cancer in smokers. The beneficial role of PEITC in lung cancer (6) and prostate cancer (13) has been documented. In the past decade, significant findings have emerged in the area of breast cancer research, which will be reviewed in this publication. Overall, this review will discuss the (I) pharmacokinetics of PEITC, (II) membrane transport of PEITC, and (III) pharmacodynamics of PEITC, including modulation of DMEs and molecular mechanisms underlying anti-cancer effects of PEITC in breast cancer.
PHARMACOKINETICS OF PEITC Pharmacokinetic Profiles in Humans and Rats
Ji et al. (15, 16) determined the sample stability, plasma protein binding, and dose-dependent pharmacokinetics of PEITC in male Sprague Dawley rats, as well as the pharmacokinetics of PEITC following the ingestion of watercress in humans. For these studies, a validated novel analytical approach was utilized that involved ammonia derivatization of PEITC to phenethylthiourea and liquid chromatography-tandem mass spectrometry (LC/MS/MS) quantitation (15) . Prior to the rat and human studies, the temperature-and pH-dependent stability of PEITC in biological samples was evaluated in order to avoid loss of PEITC during sampling or analysis. The first-order degradation half-life (t 1/2d ) of PEITC decreased from 68.2 to 15.3 h with an increase in the buffer pH from 3.0 to 10.1 at 25°C. At physiological pH of 7.4, PEITC was more stable at refrigerated temperature (t 1/2d =108 h; 4°C) than at room temperature (t 1/2d =56 h; 25°C). Binding of PEITC in rat serum was very high (about 98.1%) and concentration-independent over the range evaluated (10-1,000 μM).
A clinical study was performed in which four healthy subjects were given 100 g of watercress and their plasma and urine samples were collected (at time points up to 24 h) and PEITC plasma concentrations were determined using LC/MS/ MS. A one-compartment pharmacokinetic model with firstorder absorption and elimination was utilized to describe the pharmacokinetics of PEITC. The average peak plasma concentration (C max ) was 928.5 nM (SD 250 nM), the time to reach C max (t max ) was 2.6 h (SD 1.1 h), the first-order absorption rate constant (k a ) was 1.3/h (SD 0.3/h), and half-life (t 1/2 ) was 4.9 h (SD 1.1 h) (15) . Absorption of PEITC following watercress ingestion is a two-step process involving enzymatic conversion of gluconasturtiin into PEITC by gut flora and subsequent absorption from the gastrointestinal tract; therefore, the k a value of PEITC would thus be influenced by the slower of these two processes. Chung et al. (10) reported a dose-dependent urinary excretion of PEITC after various watercress doses in humans.
For the pharmacokinetic studies in rats (16) , PEITC doses were administered intravenously (IV) (2, 10, 100, and 400 μmol/kg) and orally (10 and 100 μmol/kg) and samples were collected at time points up to 96 h. With these increasing IV doses of PEITC, its clearance (CL) (0.70, 0.68, 0.36, and 0.50 L/h/kg) decreased with increasing dose and its volume of distribution (1.94. 3.27, 2.66, and 5.72 L/kg) increased with increasing dose, indicating saturable metabolism and nonlinear tissue distribution. Interactions of ITCs with ATPbinding-cassette (ABC) transporters account for the observed nonlinear distribution of PEITC and have been reviewed (discussed later) (12) . The half-life of PEITC was significantly longer for the 400 μmol/kg dose (13.1 h) and the 100 μmol/kg dose (9.19 h) than following the 2 μmol/kg dose (3.52 h), reflecting the dose-dependent disposition of PEITC. Absolute bioavailability (F) was 1.15 and 0.93 for the 10 and 100 μmol/ kg oral doses, respectively; thus, the extent of absorption of PEITC is complete in rats. The first-order absorption rate constant was comparable between this study (1.8/h) and the previously described clinical study (1.3/h) (15) . The t max was obtained at 0.44 and 2.0 h at doses of 10 and 100 μmol/kg, respectively, indicating the rapid absorption of PEITC. PEITC plasma concentrations also demonstrated a less-thandose proportional increase in C max and plasma AUC at both oral doses. The data was best fit to a three-compartment model with Michaelis-Menten terms to describe both the central elimination and the tissue distribution terms (Fig. 2a, b) .
In another study (17) , male Wistar rats (250±10 g; n=4 per group) were given 0.5, 1.0, and 5.0 mg/kg (3.1, 6.2, and 15.5 μmol/kg) of PEITC (in 1% DMSO) by gastric intubation as a single dose, and as multiple doses, once a day for 4 days, to examine the effect of lower oral doses and multiple dosing of PEITC. A dose of 0.5 mg/kg (3.1 μmol/kg) PEITC was given by IV administration to obtain F and for comparison of pharmacokinetic parameters between the two routes of administration. Samples were collected on the first and last days of PEITC administration, and concentrations were measured using LC/ MS. Noncompartmental analysis was used to obtain absorption, distribution, and elimination parameters for single and repeated dosing regimens. Bioavailability decreased with an increase in oral single doses: 0.77±0.13 (0.5 mg/kg oral dose), 0.61±0.11 (1 mg/kg), and 0.23±0.05 (5 mg/kg). These estimates are dependent on the assumption of similar clearance values following the oral doses and that following the 0.5-mg/kg IV dose. With repeated dosing regimens, estimated F values tended to be higher than after single doses. The absorption rate constant was not dose-dependent indicating first-order absorption. PEITC was rapidly absorbed as the t max was less than an hour; however, values of C max increased less-than-dose proportionally for all single and repeated dosing regimens. Taken together, these two studies (15, 17) suggest that PEITC demonstrates dose-dependent pharmacokinetics, where absorption does not contribute to its observed nonlinear behavior. The differences in bioavailability reported in the two studies require further study.
Metabolism of PEITC
PEITC is predominantly cleared by metabolism in humans and animals. In humans and rats, glutathione S-transferases (GST) (18) catalyze the conversion of PEITC to its glutathione conjugate (PEITC-SG) in the liver. γ-Glutamyl and glycyl moieties of PEITC-SG are cleaved by γ-glutamyl transferase and dipeptidase, respectively. The resulting cysteine conjugate undergoes N-acetylation of its cysteine moiety by N-acetyltransferase 2 (NAT2) and is excreted as mercapturic acid in the urine (18, 19) . Formation of mercapturic acid conjugates by NAT2 can occur in the kidneys although metabolism has also been demonstrated in the liver and the location is likely speciesdependent (20) . PEITC is metabolized by GST isoforms, GSTμ1 and GSTθ1 (17) , which are present in the intestine, liver, and kidney. Conjugation of PEITC with glutathione would depend on intracellular concentrations of glutathione (21) and on genetic variants and polymorphisms in GST isoforms, and both of these factors may be responsible for the observed differences in plasma concentrations (22) . In fact, increased chemopreventive effects have been associated with GST polymorphisms (23) that result in decreased metabolism of PEITC and therefore higher plasma concentrations. GSTs also catalyze the reversible metabolism of PEITC/PEITC-SG (24) . The PEITC-SG conjugate is labile and can spontaneously convert to PEITC and GSH at physiological pH with an estimated t 1/2 of 44 min. This reversible metabolism adds to the complex PK of PEITC observed in studies.
The first metabolic study of PEITC was reported in A/J mice, where mice were dosed with 5 μM (2 μCi/mouse) of [ 14 C] PEITC by oral gavage and organs were collected via terminal sampling at various time points up to 72 h. Since a nonspecific (radioactivity) assay was used to measure PEITC accumulation in the collected organs, these results cannot be used to elucidate the distribution profile of unchanged PEITC. At 72 h postadministration, almost 80% of radioactivity was collected in urine. An HPLC assay was used to identify a cyclic mercaptopyruvic acid conjugate (major metabolite; 25% of the administered dose) and N-acetyl cysteine conjugate (minor metabolite; 10% of the administered dose)-the two metabolites of PEITC in urine (25) . In another study, dose-dependent excretion of an N-acetyl cysteine conjugate was measured (using NMR/MS) after ingestion of 30 and 57 g of watercress in four human individuals (10) . Unlike mice, only the N-acetyl cysteine conjugate is excreted in humans (10, 26) and in rats (19) . Figure 1 illustrates the synthesis and metabolism of PEITC in rats and humans. Membrane Transport of PEITC Studies have evaluated whether PEITC is a substrate and/or inhibitor of the ABC transporters P-glycoprotein (ABCB1), multidrug resistance-associated proteins 1 and 2 (MRP1, ABCC1; MRP2, ABCC2), and breast cancer-resistant protein (BCRP, ABCG2). The IC 50 values of PEITC were similar in MCF-7/ Adr-overexpressing P-glycoprotein (P-gp; ABCB1)-and MCF-7/wt cell lines, suggesting that P-gp interactions may not contribute to cytotoxicity in these cell lines through changes in PEITC intracellular concentrations. Accumulation of PEITC was measured in PANC-1 (overexpressing multidrug resistance-associated protein 1, MRP1; ABCC1) and in MCF-7/Adr, MDA435/LCC6, and Caco-2 (all overexpressing P-gp) cell lines at 2 h postincubation (21) . In the presence of verapamil, a P-gp inhibitor, accumulation of PEITC remained unchanged in all three P-gp overexpressing cell lines, confirming that PEITC was not a substrate for P-gp. However, accumulation of PEITC significantly increased in PANC-1 cells in the presence of MK571, an inhibitor of MRP1. As MRPs mediate efflux of substrates via conjugation with intracellular glutathione or in association with glutathione, further studies confirmed that PEITC inhibits the MRP1-mediated efflux of daunomycin (DNM) by competing for glutathione and through MRP1 interactions (21) . Glutathione depletion, which results in impaired transport by MRPs, was further evaluated using the MDCKII/MRP2 cell line (27) ; inhibition of glutathione synthesis by buthionine sulfoxinine resulted in increased accumulation of PEITC. In same study, PEITC was reported to be a substrate for MRP2 (ABCC2) (27) . Depletion of glutathione at high concentrations of PEITC explains the nonlinear volume of distribution and prolonged tissue binding of PEITC (16) (28) . PEITC was also reported to be a substrate for BCRP and an inhibitor of BCRP-ATPase activity using inside-out membrane vesicles prepared from MCF-7/MX100 cells (29) . Overall, the results from cell culture studies suggest that PEITC and/or PEITC-SG represents an inhibitor and substrate for MRP1 and MRP2 (21, 27) and that PEITC itself is also an inhibitor and substrate for breast cancer resistance protein (BCRP; ABCG2) (28) . Thus, transport of PEITC or PEITC glutathione conjugates by ABC transporters represents an important feature of PEITC PK/PD.
Overall, the observed pharmacokinetic behavior of PEITC (10, (15) (16) (17) (Fig. 3) indicates that (I) PEITC is rapidly absorbed by a first-order absorption process, (II) PEITC undergoes saturable metabolism at high doses and potential deconjugation of PEITC-SG; (III) PEITC-SG is converted to mercapturic acid by Nacetylation, which is excreted into urine; (VI) PEITC is highly protein bound; and (V) PEITC, being lipophilic, is rapidly distributed into tissues where it can undergo glutathione (SG) conjugation and both the parent PEITC and the PEITC-SG conjugate are actively effluxed from cells by MRP1/2 (ABCC1/2). Saturation of the efflux transporter or inhibition of transport due to the depletion of intracellular glutathione (21) contributes to the nonlinear increase in volume of distribution with increasing doses.
CANCER PREVENTION/TREATMENT EFFECTS OF PEITC
An important pharmacodynamic effect of PEITC is its cancer prevention properties against a broad range of cancers. Epidemiological studies have indicated that the risk of lung, colon, breast, stomach, and prostate cancers is decreased with increasing dietary intake of PEITC. High urinary ITC levels are significantly associated with reduced breast cancer risk in pre-and postmenopausal women (30). Terry et al. (31) reported that consumption of cruciferous vegetables lowers the risk of breast cancer by as much as 20-40% in postmenopausal women.
Modulation of DMEs by PEITC
First reports of the anti-carcinogenic potential of PEITC by inhibition of nitrosamine metabolism occurred in the mid-1980s to early 1990s. Nitrosamines are by-products of industrial waste, which are activated in the liver by CYP450 enzymes (α-hydroxylation) to form diazohydroxide intermediates. They cause alkylation of cellular components, particularly DNA, resulting in the initiation of tumorigenesis (32) . Mechanisms of tumor initiation are summarized in a review by Hecht (6). Chung et al. (33) assessed the inhibition of α-hydroxylation of two carcinogenic nitrosamines, N-nitrosodimethylamine (NDMA) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), by PEITC in vitro in liver microsomes of F344 rats and in vivo in F344 rats and found decreased nitrosamine metabolism in vitro and reduced DNA damage in rat livers in vivo with acute (2 h) and chronic (2 weeks) PEITC treatment. Several studies (34) (35) (36) (37) further investigated the role of PEITC in alterations of drug-metabolizing enzymes leading to changes in procarcinogen activation and carcinogen elimination.
Ishizaki et al. (34) showed that PEITC suppressed the activity and expression of CYP2E1 in vitro in rat liver microsomes and in vivo in rats. In liver microsomes isolated from acetone-treated rats, PEITC inhibited CYP2E1-mediated α-hydroxylation of NDMA with an apparent K i of 1.0 μM. The observed inhibition of NDMA demethylation by PEITC was both time-and concentration-dependent. Immunoblotting studies showed a marked decrease in CYP2E1 expression but an 11-fold increase in the activity of CYP2B1 determined 24 h after a single oral dose of PEITC (1 mmol/kg) in vivo (34). Gao et al. (36) characterized effects of PEITC on phase I and phase II metabolizing enzymes in the liver, lung, and nasal mucosa of F344 rats after a single oral dose of 1 mmol/kg PEITC and found PEITC-mediated modulation of DMEs to be tissue specific. In the liver (L), lung (Lu), and nasal mucosa (N), the activities of DMEs were inhibited (↓), induced (↑), or remained unchanged (↔): NDMA-demethylase (CYP2E1) (L=80% ↓ at 2 h and remained 40% ↓ at 48 h), pentoxyresorufin O-dealkylase (CYP2B1) (L =10-fold ↑; Lu=↔; N=40-50% ↓), NMKdemethylase (CYP2E1) (L=60% ↓ at 2 h; Lu=70% ↓ at 2 h; N=50% ↓ at 18 h), NAD(P)H quinone oxidoreductase (L=5-fold ↑; Lu=↔; N=↔), GST (L=1.5-fold ↑; Lu=↔; N=↔), and sulfotransferase (L=32-48% ↓ between 24 and 48 h; Lu=↔; N=1.5-2.5-fold ↑ between 24 and 48 h). The activity of UDPglucuronosyltransferase (UGT) increased moderately at 24 h. The alterations in DMEs by PEITC were reversible in nature (36).
Morse et al. (37) examined the effect of PEITC in NNKinduced lung tumorigenesis using tumor biopsies of A/J mice and F344 rats. Their results were consistent with previous data (33, 34) , suggesting that the inhibition of lung tumorigenesis by PEITC was a result of inhibition of the NNK metabolism pathway in the liver. Doerr-O'Rourke et al. (35) observed similar inhibitory effects of PEITC on NNK metabolism in cultured rat lung tissues. Moreover, the metabolism of NNK by CYP1A2, CYP2A6, CYP2D6, CYP2E1, and CYP3A4 has been reported in humans (38) (39) (40) .
Further studies characterized the inhibitory potential of PEITC on both phase I and II enzymes. This was first studied in microsomes from baculovirus-infected insect cells overexpressing human CYP isoforms (41). Inhibition constants (K i ) were measured (mean±SD) over a wide range of concentrations of PEITC for various probe-substrates of CYP isoforms. PEITC inhibited activities of CYP1A2/phenacetin (4.5± 1.0 μM) and CYP2A6/coumarin (18.2±2.5 μM) via competitive inhibition; of CYP2B6/benzyloxyresorufin (1.5±0.0 μM), CYP2C9/S-warfarin (6.5±0.9 μM), CYP2C19/S-mephenytoin (12.0 ± 3.2 μM), CYP2D6/bufuralol (28.4 ± 7.9 μM); and CYP2E1/chlorzoxazone (21.5±3.4 μM) via noncompetitive inhibition; and of CYP3A4/testosterone via both competitive (34.0±6.5 μM) and noncompetitive (63.8±12.5 μM) inhibition. Data suggest that PEITC could alter the pharmacokinetics of these clinically used drugs; however, not all PEITCdrug interactions lead to clinically significant drug-drug interactions (42, 43) . Konsue et al. (44) characterized the modulation of the activity and expression of CYPs and phase II enzymes by dietary doses (0.06, 0.6, and 6.0 μmol/g) of PEITC in male Wistar albino rats (180±10 g) and found that changes in activities of DMEs were tissue-specific and dose-dependent. After 14 days of PEITC administration, activities and qualitative changes in protein expression of several DMEs were measured in the rat liver, lungs, and kidneys using probe-substrates and immunoblotting assays, respectively. In the liver, expression of CYP2B1 and CYP3A4 increased and expression of CYP1A1, CYP1A2, CYP1B1, and CYP2E1 decreased in a dose-dependent manner. In contrast to the liver, expression of CYP1A1, CYP1A2, and CYP1B1 increased moderately in a dose-dependent manner in the lungs and CYP2E1 expression showed a significant increase. In the kidneys, expression of these enzymes did not change. In the liver, expression of GSTα, GSTμ, and GSTп increased sharply with dose; however, expression remained unchanged in the lungs and kidneys. Konsue et al. (45, 46) further performed in vitro studies using precision-cut rat and human liver slices to assess modulation of DMEs by PEITC (0-50 μM). In rat liver slices, expression of GSTα, GSTμ, GSTп, and NAD(P)H quinone oxidoreductase increased but no conclusions could be drawn for human liver slices due to the high variability observed. In both rat and human liver slices, expression of CYP1A1, CYP1A2, and CYP2B6 decreased and CYP3A4 and CYP3A2 increased in a concentrationdependent manner (46) . It was also reported that unchanged PEITC (not its metabolites) modulates the activity and expression of DMEs in rats and humans (47) .
Telang et al. (48) evaluated the effect of oral PEITC administration of a 150 μmol/kg dose daily for 5 days on hepatic gene regulation in male Sprague Dawley rats using a gene array of 282 genes and quantitative RT-PCR assays. Gene expression ratios (treatment/control) of Cyp2b15 (3.01) and Ugt1a6 (5.67) indicated strong upregulation of these genes and a strong downregulation of nicotinamide Nmethyltransferase (NNMT), an important cancer marker; observed changes in mRNA expression of NNMT and Ugt1a6 were confirmed by quantitative RT-PCR assays. An apoptotic gene Bcl2l2 and several stress regulator genes (Dnajb9, Dnajc5, and Hspb1) were also upregulated in the liver, suggesting alterations in gene transcription by PEITC.
Molecular Mechanisms Underlying Anti-cancer Effects of PEITC in Breast Cancer
Several molecular targets of PEITC for chemoprevention have been extensively reviewed (14) and only those relevant to breast cancer will be discussed in this section. Tseng et al. using an array of 112 genes determined in normal human mammillary epithelial (HME) cells and breast cancer MCF-7 cells. At 0.3 and 3.0 μM concentrations of PEITC, expression levels of 23 and 4 genes were significantly altered in HME cells at these two PEITC concentrations, respectively, and no changes in the expression of genes were detected in MCF-7 cells. Novel findings were upregulation of BCL2-antagonist of cell death (BAD) (24.08-fold ↑; apoptotic gene), estrogen receptor 2 (ERβ) (7.55-fold ↑), p21 (5.28-fold ↑; tumor suppressor), and p27 (14.79-fold ↑; tumor suppressor) at a PEITC concentration of 0.3 μM in HME cells. In an additional study in MCF-7 cells examining other relevant breast cancer genes, upregulation of p57 (5.23-fold ↑), Brca2 (4.22-fold ↑), Il-2 (3.16-fold ↑), Atf-2 (2.6-fold ↑), p53 (2.12-fold ↑), and Hsp27 (1.84-fold ↑) genes was detected following incubation with 3.0 μM of PEITC (51) . Taken together (50, 51) , increases in (I) p21, p27, and p57 result in cell cycle arrest (G2 phase); (II) Il-2 results in cell cycle arrest (G2 phase); (III) Hsp27 and Atf-2 result in increased DNA repair and protection from subsequent DNA damage; and (IV) p53 and Brca2 result in increased DNA repair and apoptosis of cells with damaged DNA.
Studies (52, 53) have identified suppression of ERα protein expression by PEITC (0-20 μM) as a potential mechanism of breast cancer inhibition in MCF-7, T-47D, and H3396 cell lines. PEITC (10 μM) was a more potent ERα inhibitor than a conventional inhibitor, ICI 182,780 (10 μM). It caused cell growth inhibition, as a consequence of impaired signaling of mitogenic estrogen by ERα. Interactions of PEITC with B cell lymphoma 2 interacting mediator (Bim) protein (54) led to apoptosis of breast cancer cells and was independent of PEITC-induced p53 upregulation. Knockdown by small interfering RNA of Bim in MCF-7 and MDA-MB-231 cell lines showed partial but significant absence of apoptosis (54) . Inhibition of heat shock proteins (HSPs) 27, 70, and 90 and of heat shock factor 1 by PEITC in MDA-MB-231 and MCF-7 cell lines resulted in an impaired cell cycle regulation (downregulation of Cyclin B1, CDK1, Cdc25C, PLK-1), cell cycle arrest (G2/M phase), and apoptosis (activation of caspases 3 and 9) of breast cancer cells (55) . A synergistic effect of paclitaxel and PEITC was reported on cell cycle arrest at the G2/M phase that is more pronounced than either paclitaxel or PEITC alone in MCF-7 and MDA-MB-231 cell lines, respectively (56) . Cell cycle arrest at the G2/M phase by PEITC in MCF-7 and MDA-MB-231 cell lines has also been attributed to generation of reactive oxidative species (ROS) due to intracellular glutathione depletion (57) .
Recently reported studies (9, (58) (59) (60) have begun to elucidate the role of PEITC in breast cancer in vivo using various animal models. PEITC significantly (I) decreased the protein expression of HER2 receptor and epidermal growth factor receptor (EGFR) and phosphorylation of signal transducer and activator of transcription 3 (STAT3) and (II) increased apoptosis by selectively cleaving caspase 3 and poly-ADP ribose polymerase (PARP) proteins in MCF-7/HH and MDA-MB-231/HH cell lines overexpressing HER2 (HH) in vitro and in female SCID/NOD mice (12 μmol PEITC orally until day 35) implanted with MDA-MB-231/HH cells in ) was first to report the role of PEITC in the initiation and progression of N-methyl nitrosourea (NMU)-induced breast cancer in female rodents. Female Sprague Dawley rats (8 weeks old) were given 50 or 150 μmol/kg PEITC orally, starting prior to NMU administration, and tumor progression was observed for 18 weeks. The PEITC treatment prolonged the tumor-free survival time and decreased the tumor incidence and multiplicity. The time to the first palpable tumor was prolonged from 69 days (control) to 84 days (50 μmol/kg PEITC) and 88 days (150 μmol/kg PEITC). The tumor incidence was 56.6%, 25.0%, and 17.2% in the control, 50, and 150 μmol/kg PEITC-treated groups, respectively, while the tumor multiplicity was 1.03, 0.25, and 0.21, respectively. There were no significant differences between the two doses. The intratumoral capillary density decreased from 4.21±0.30 vessels per field (vpf) (control) to 2.46±0.25 vpf (50 μmol/kg) and 2.36±0.23 vpf (150 μmol/kg) in PEITC-treated animals. Anti-angiogenic effects of PEITC in a chemically induced breast cancer animal model were reported thus for the first time. Anti-angiogenic effects of PEITC have been also reported in a prostate cancer animal model (61) . Table I and Fig. 4 summarize studies that have examined the anti-breast cancer effects of PEITC.
CONCLUSIONS
Phenethyl isothiocyanate, a naturally occurring ITC, is a component of cruciferous vegetables. It modulates the activity and protein expression of a wide range of phase I oxidative and phase II conjugating DMEs inhibiting the formation of carcinogens and increasing their detoxification. PEITC demonstrates dose-dependent pharmacokinetics with (I) first-order absorption, (II) nonlinear tissue distribution due to interactions with ABC transporters and intracellular glutathione depletion, and (III) capacity-limited elimination due to saturation of GSTs in the liver. Pharmacodynamics of PEITC in breast cancer involves several cell membrane specific, cytosolic, and nuclear mechanisms, ultimately resulting in cell cycle arrest and apoptosis of breast cancer cells. An interesting and recent mechanism described for PEITC is anti-angiogenesis which may contribute to its cancer preventive effects in breast cancer. Since PEITC demonstrates a wide range of pharmacodynamic outcomes at the cellular, organ, and species levels, there is the need for a systems-biology approach in parallel with PK/PD modeling to develop PEITC as a therapeutic agent for treating cancers.
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